Micro-Cap Biotech Raises $1.5M Upfront, Up to $5M, to Fund First U.S. Anxiety Trial
PTIX has more than doubled off its 52-week low of $0.128 on light trading volume (0.4× avg).
Summary
Protagenic pulled in $1.5M in upfront gross proceeds from a private placement with new and existing investors, with up to $3.5M more if two series of milestone-linked warrants are exercised in full, for up to $5M total before fees. The initial closing issued 2,459,014 shares plus Series A warrants at $0.67 and Series B warrants at $0.73, with subsequent closings allowed until December 31, 2026. The cash is earmarked for IND-enabling work on PT00114, starting the Phase 1/2a trial in generalized anxiety disorder, and working capital. This comes after the August 20 8-K disclosing FDA pre-IND feedback with no deficiencies blocking an IND, and it addresses the going-concern warning and thin cash position flagged in the August 19 10-Q. The company targets first patient dosing in Q2 2027, topline safety data in H2 2027 and exploratory efficacy data in H1 2028. The upfront $1.5M is small relative to the full trial cost, and management explicitly says it continues to pursue strategic options and additional capital, so further dilution is likely.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Initial closing issued 2,459,014 shares plus Series A warrants at $0.67 and Series B warrants at $0.73, with subsequent closings allowed until December 31, 2026.
At the time of this announcement, PTIX was trading at $0.49 on OTC in the Life Sciences sector, with a market capitalization of approximately $893.2K. The 52-week trading range was $0.13 to $4.43. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.